Xeris Biopharma Holdings, Inc.

NASDAQ:XERS

Biotechnology

Healthcare
$16.99 +0.58%

+$0.04 today

Market cap
$3.10B
Beta
0.90
P/E (TTM)
98.7
EPS (TTM)
$0.07
52W Low $4.40High $10.08

Volume 2.76M

Average 1.66M

XERS Cash & Equivalents

Cash on hand and highly liquid investments that can be converted to cash almost immediately.

Xeris Biopharma Holdings, Inc.NASDAQ: XERS

Cash & Equivalents · Q1 FY2026 · quarter ended Mar 2026

Cash & equivalents rises 91.2% from a year ago

Cash & equivalents stood at $111.75M at the end of Q1 FY2026, up 91.2% from a year earlier and up 0.6% from the prior quarter. Over 3 fiscal years it compounded at -3.1% a year.

Context

  • Cash & equivalents amounted to 28.5% of total assets at the end of Q1 FY2026, up 10.0 pp from a year earlier.
  • Cash & equivalents increased in 2 of the last 3 fiscal years.

What to watch

Whether cash & equivalents keeps rising in the next quarterly balance sheet after a +91.2% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$111.75M+0.6% QoQ
Last fiscal yearDec 2025
$111.04M+55.0% YoY
Year agoMar 2025
$58.44M+91.2% since
Cash & Equivalents past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+91.2%——
1 year+55.0%——
3-year CAGR-3.1%——
5-year CAGR——
10-year CAGR——

Cash & Equivalents history

USD · from the balance sheet

Latest · FY2025
111.04M USD
Year-over-year change
+55.0%
4-year CAGR
+13.3%

Cash & Equivalents vs competitors

How XERS compares with its peers on the latest reported figures

  • Peers report in different currencies, so cash & equivalents is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of +91.2% is the 2nd highest of 9, against a peer median of +9.9%.
  • Cash & equivalents amounts to 28.5% of total assets for XERS, versus a peer median of 29.6%.
XERS Competitors
Cash & Equivalents for XERS and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
ASNDAscendis Pharma A/SSep 2026€964.36M EUR+78.9%+11.5%39.7%
GHRSGH Research PLCMar 2026$242.65M USD-0.9%+14.1%88.2%
SEPNSepterna, Inc.Sep 2026$167.12M USD-47.8%+58.0%27.0%
MBXMBX Biosciences, Inc. Common StockSep 2026$161.69M USD-27.5%+46.0%32.3%
XERSXeris Biopharma Holdings, Inc.Mar 2026$111.75M USD+91.2%-3.1%28.5%
CORTCorcept Therapeutics IncorporatedJun 2026$111.04M USD+8.1%+22.0%12.5%
SPRBSpruce Biosciences, Inc.Mar 2026$54.08M USD+111.1%+25.9%96.3%
MNKDMannKind CorporationMar 2026$52.83M USD+11.7%+2.4%7.1%
ETONEton Pharmaceuticals, Inc.Mar 2026$19.66M USD+12.9%+16.7%20.1%
Peer median (excluding XERS) —+9.9%+19.4%29.6%

Competitors are the stored peer set for XERS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents67.27M121.97M67.45M71.62M111.04M
Short-term Investments35.16M05M00
Net Receivables17.46M30.83M39.2M40.42M51.05M
Inventory18.12M24.74M38.84M48.18M68.67M
Other Current Assets09.29M5.78M7.45M9.55M
Total Current Assets142.6M186.82M156.26M167.66M240.31M
Property, Plant & Equipment (Net)6.63M9.51M29.18M28.21M27.06M
Goodwill22.86M22.86M22.86M22.86M22.86M
Intangible Assets131.45M120.61M109.76M98.92M88.08M
Long-term Investments0004.12M0
Tax Assets0006.09M0
Other Non-current Assets829K4.73M4.54M(4.81M)5.22M
Total Non-current Assets161.77M157.7M166.34M155.4M143.21M
Total Assets304.36M344.52M322.6M323.06M383.53M
Account Payables8.92M4.61M11.57M2.29M3.08M
Short-term Debt00015.1M6.23M
Tax Payables00000
Deferred Revenue00000
Other Current Liabilities25.63M27.23M51.43M39.75M100.27M
Total Current Liabilities79.04M73.62M95.19M100.44M109.57M
Long-term Debt88.07M187.08M190.93M217.01M31.53M
Deferred Tax Liabilities4.94M3.52M2.27M00
Deferred Revenue (Non-current)00000
Other Non-current Liabilities37.08M25.72M6.23M1.97M228.73M
Total Non-current Liabilities130.09M225.71M234.19M252.23M260.26M
Total Liabilities209.13M299.34M329.38M352.68M369.84M
Common Stock13K14K14K15K17K
Retained Earnings(460.11M)(554.77M)(617.03M)(671.86M)(671.31M)
Accumulated OCI(31K)(23K)(25K)(25K)(25K)
Other Stockholders Equity00000
Minority Interest00000
Total Equity95.23M45.19M(6.78M)(29.62M)13.69M
Total Debt88.07M198.06M229.19M271.45M37.76M
Net Debt20.8M76.09M161.74M199.83M(73.28M)

Xeris Biopharma Holdings, Inc.

NASDAQ:XERS

Intrinsic Alpha fair value

Locked

Current Price

$16.99

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.